The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...

Biguanides vs dipeptidyl peptidase-4 (DPP-4) inhibitors have a similar incidence of cardiac and cerebrovascular events, as well as disease-related complications, but are less costly to use in patients ...

Creating a novel drug has always been a risky endeavor for biopharmaceutical companies. Developers and investors face ...

Diabetes is a chronic medical condition that affects the body’s ability to regulate blood sugar or glucose, a vital energy ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

It seems like a day doesn’t go by without another positive finding for the glucagon-like peptide 1 (GLP-1) receptoragonist ...

Substantial proportions of both groups also received metformin, a sulfonylurea, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and/or insulin. In multivariate analysis, the SGLT2i group had a 70% lower ...

A recent multinational, federated analysis of LEGEND-T2DM study published that Sodium-glucose cotransporter 2 inhibitors ...

Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK ...